Revenues

Product Revenues

Revenues by product are summarized as follows:



	For the Three Months Ended June 30,
(In millions)	2018						2017
	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis:
TECFIDERA	$	825.8	$	261.0	$	1,086.8	$	875.0	$	235.6	$	1,110.6
Interferon*	444.7		180.8		625.5		501.7		188.9		690.6
TYSABRI	265.5		201.7		467.2		289.4		206.6		496.0
FAMPYRA	—		23.0		23.0		—		22.6		22.6
ZINBRYTA	—		—		—		—		16.1		16.1
Spinal Muscular Atrophy:
SPINRAZA	205.9		216.8		422.7		194.8		8.1		202.9
Other Product Revenues:
FUMADERM	—		5.5		5.5		—		10.3		10.3
BENEPALI	—		115.6		115.6		—		88.7		88.7
FLIXABI	—		11.2		11.2		—		1.9		1.9
Total product revenues	$	1,741.9	$	1,015.6	$	2,757.5	$	1,860.9	$	778.8	$	2,639.7

*Interferon includes AVONEX and PLEGRIDY.



	For the Six Months Ended June 30,
(In millions)	2018						2017
	United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis:
TECFIDERA	$	1,554.7	$	519.0	$	2,073.7	$	1,626.1	$	442.7	$	2,068.8
Interferon*	816.0		359.8		1,175.8		966.5		372.4		1,338.9
TYSABRI	515.2		414.1		929.3		594.9		446.1		1,041.0
FAMPYRA	—		47.4		47.4		—		43.1		43.1
ZINBRYTA	—		1.4		1.4		—		26.8		26.8
Spinal Muscular Atrophy:
SPINRAZA	393.9		392.7		786.6		241.2		9.1		250.3
Hemophilia:
ELOCTATE	—		—		—		42.2		6.2		48.4
ALPROLIX	—		—		—		21.0		5.0		26.0
Other Product Revenues:
FUMADERM	—		12.5		12.5		—		20.0		20.0
BENEPALI	—		236.5		236.5		—		154.0		154.0
FLIXABI	—		17.8		17.8		—		2.5		2.5
Total product revenues	$	3,279.8	$	2,001.2	$	5,281.0	$	3,491.9	$	1,527.9	$	5,019.8

*Interferon includes AVONEX and PLEGRIDY.

We recognized revenues from two wholesalers accounting for 32.5% and 18.6% of gross product revenues for the three months ended June 30, 2018, and 33.2% and 17.3% of gross product revenues for the six months ended June 30, 2018.

We recognized revenues from two wholesalers accounting for 34.3% and 22.8% of gross product revenues for the three months ended June 30, 2017, and 35.5% and 21.1% of gross product revenues for the six months ended June 30, 2017.

An analysis of the change in reserves for discounts and allowances is summarized as follows:



(In millions)	Discounts			Contractual Adjustments			Returns			Total
Balance, as of December 31, 2017	$	109.6		$	606.0		$	46.0		$	761.6
Current provisions relating to sales in current year	333.2			1,288.0			11.4			1,632.6
Adjustments relating to prior years	(0.3		)	7.4			2.6			9.7
Payments/credits relating to sales in current year	(222.3		)	(731.9		)	—			(954.2		)
Payments/credits relating to sales in prior years	(101.0		)	(469.6		)	(13.5		)	(584.1		)
Balance, as of June 30, 2018	$	119.2		$	699.9		$	46.5		$	865.6

The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:



(In millions)	As of June 30, 2018		As of December 31, 2017
Reduction of accounts receivable	$	162.8	$	189.6
Component of accrued expenses and other	702.8		572.0
Total reserves	$	865.6	$	761.6

Revenues from Anti-CD20 Therapeutic Programs

Revenues from anti-CD20 therapeutic programs are summarized as follows:



	For the Three Months Ended June 30,				For the Six Months Ended June 30,
(In millions)	2018		2017		2018		2017
Biogen’s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	359.0	$	347.5	$	708.6	$	671.0
Other revenues from anti-CD20 therapeutic programs	131.4		49.6		225.0		66.7
Total revenues from anti-CD20 therapeutic programs	$	490.4	$	397.1	$	933.6	$	737.7

For additional information on our collaboration with Genentech, please read Note 20, Collaborative and Other Relationships, to our consolidated financial statements included in our 2017 Form 10-K.

Other Revenues

Other revenues are summarized as follows:



	For the Three Months Ended June 30,						For the Six Months Ended June 30,
(In millions)	2018			2017			2018			2017
Revenues from collaborative and other relationships:
AbbVie	$	(2.5	)	$	(3.9	)	$	(7.2	)	$	(9.8	)
Samsung Bioepis and other	14.7			12.9			32.6			25.1
Other royalty and corporate revenues:
Royalty	17.3			11.8			27.9			37.3
Other corporate	79.1			20.8			219.7			79.0
Total other revenues	$	108.6		$	41.6		$	273.0		$	131.6

For additional information related to our collaborations with AbbVie and Samsung Bioepis, please read Note 18, Collaborative and Other Relationships, to these condensed consolidated financial statements.